Recombinant Coagulation Factors Market Size, Share, Growth Analysis, By Product(Recombinant factor VIII, Recombinant factor IX, Von Willebrand factor), By Application(Hospitals, Clinics, Research Organizations), By Region - Industry Forecast 2024-2031

Recombinant Coagulation Factors Market size was valued at USD 12.66 billion in 2022 and is poised to grow from USD 13.46 billion in 2023 to USD 21.94 billion by 2031, at a CAGR of 6.3% during the forecast period (2024-2031).

There are several major players in recombinant coagulation factors market. Several strategies are used by major market players to survive in the competition, such as mergers & acquisitions, partnerships, new product launches, and collaborations. 'Novo Nordisk A/S', 'Shire plc', 'CSL Behring', 'Sanofi S.A.', 'Pfizer Inc.', 'Bayer AG', 'Biogen Inc.', 'Grifols, S.A.', 'Kedrion S.p.A.', 'Octapharma AG', 'Green Cross Corporation', 'Baxalta (now part of Takeda Pharmaceutical Company Limited)', 'LFB S.A.', 'Genzyme Corporation (now part of Sanofi S.A.)', 'Bioverativ Inc. (now part of Sanofi S.A.)', 'Swedish Orphan Biovitrum AB (publ)', 'BDI Pharma, Inc.', 'Emergent BioSolutions Inc.', 'Prometic Life Sciences Inc.', 'Albumedix Ltd.', 'In June 2023, Thermo Fisher Scientific developed a new biologics manufacturing facility in Lengnau, in the Swiss canton of Bern, to improve its pharmaceutical services capacity and manufacturing capabilities to meet the growing demand for biologic therapies. ', 'In May 2022, Takeda Pharmaceutical Co Ltd announced the expansion of its rare diseases portfolio in India with the launch of Adynovate, used in the treatment of hemophilia. ', 'In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announced the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities.   ', 'In September 2021, Octapharma announced that the European Commission had granted marketing authorization for its recombinant human von Willebrand factor / recombinant human coagulation factor VIII (rVWF/rFVIII) concentrate, Wilfactin®. This product is indicated for the treatment and prevention of bleeding in patients with von Willebrand disease. ', 'In August 2021, Pfizer acquired Amplyx Pharmaceuticals, which gives Pfizer access to Amplyx's portfolio of antifungal compounds, including the recombinant factor H-related protein 1 (CFHR1). CFHR1 is being developed as a potential treatment for severe fungal infections in patients with compromised immune systems.'

Significant investment in research and development

Rising impact of blood disorders and growing adoption of recombinant coagulation factors are key trend that drive the recombinant coagulation factors market. Recombinant coagulation factor is a type of blood factor produced by recombinant technology. It is used in the treatment of disorders such as haemophilia.

On the basis of region, recombinant coagulation factors market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the market during the forecast period. Increasing demand for treatment and rising patient awareness about different treatment options are driving the market in North America.